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Mitochondrial 
phosphoenolpyruvate 
carboxykinase (PEPCK-M) and 
serine biosynthetic pathway genes 
are co-ordinately increased during 
anabolic agent-induced skeletal 
muscle growth
D. M. Brown1, H. Williams1,2, K. J. P. Ryan1,†, T. L. Wilson4, Z. C. T. R. Daniel1, 
M. H. D. Mareko1,‡, R. D. Emes3, D. W. Harris4, S. Jones1, J. A. D. Wattis2, I. L. Dryden2, 
T. C. Hodgman1, J. M. Brameld1 & T. Parr1
We aimed to identify novel molecular mechanisms for muscle growth during administration of anabolic 
agents. Growing pigs (Duroc/(Landrace/Large-White)) were administered Ractopamine (a beta-
adrenergic agonist; BA; 20 ppm in feed) or Reporcin (recombinant growth hormone; GH; 10 mg/48 hours 
injected) and compared to a control cohort (feed only; no injections) over a 27-day time course (1, 
3, 7, 13 or 27-days). Longissimus Dorsi muscle gene expression was analyzed using Agilent porcine 
transcriptome microarrays and clusters of genes displaying similar expression profiles were identified 
using a modified maSigPro clustering algorithm. Anabolic agents increased carcass (p = 0.002) and 
muscle weights (Vastus Lateralis: p < 0.001; Semitendinosus: p = 0.075). Skeletal muscle mRNA 
expression of serine/one-carbon/glycine biosynthesis pathway genes (Phgdh, Psat1 and Psph) and the 
gluconeogenic enzyme, phosphoenolpyruvate carboxykinase-M (Pck2/PEPCK-M), increased during 
treatment with BA, and to a lesser extent GH (p < 0.001, treatment x time interaction). Treatment 
with BA, but not GH, caused a 2-fold increase in phosphoglycerate dehydrogenase (PHGDH) protein 
expression at days 3 (p < 0.05) and 7 (p < 0.01), and a 2-fold increase in PEPCK-M protein expression at 
day 7 (p < 0.01). BA treated pigs exhibit a profound increase in expression of PHGDH and PEPCK-M in 
skeletal muscle, implicating a role for biosynthetic metabolic pathways in muscle growth.
Homeostatic control of skeletal muscle mass is largely controlled by holding rates of protein synthesis and 
protein degradation in equilibrium1. Anabolic signals perturb this balance in favor of net protein accretion. 
Administration of exogenous anabolic agents, such as synthetic beta-adrenergic agonists (BA) and recombinant 
growth hormone (GH), are well documented to enhance skeletal muscle net protein accretion2,3. Such agents have 
long been of interest due to their therapeutic potential to maintain or increase muscle mass during pathological 
conditions whereby a loss of muscle mass negatively impacts disease progression or quality of life. Use of these 
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agents has also been widely applied to agricultural industries striving to enhance accretion of lean mass in live-
stock species2. Whilst a plethora of academic laboratories have demonstrated the efficacious actions of BA and 
GH to promote lean muscle growth4–13, mechanisms underpinning this response remain unclear, thus limiting 
future drug discovery potential.
Research using animal models has robustly demonstrated that GH administration increases net protein accre-
tion in skeletal muscle by increasing protein synthesis5,6,14,15. GH administration stimulates endogenous pro-
duction of insulin-like growth factor 1 (IGF-1; predominantly in the liver), which is considered at least partly 
accountable for the anabolic effects of GH16–18. Treatment with recombinant GH activates the IGF-1-Akt-mTOR 
pathway16, which increases the translational capacity of the cell and drives protein synthesis1. Although signal 
transduction events following GH administration are well characterized in muscle, documentation of the tran-
scriptionally regulated events remains sparse19.
Whilst many reports demonstrate that BA administration reduces protein degradation8,9,13,20 others have 
shown increased protein synthesis20–22. Accordingly, molecular analyses have identified both BA-mediated acti-
vation of protein synthetic pathways, such as the Akt-mTOR pathway23, and reduction of protein degradation 
pathways, namely repression of calpain activity and increased expression of calpastatin20,24. Mounting evidence 
indicates these molecular events occur in a temporal manner during BA administration13,20,25–27 highlighting the 
importance of time course study designs when examining these agents. Two previous studies have profiled global 
transcriptional events in skeletal muscle of BA treated mice and revealed extensive deregulation of gene expres-
sion26,27. However, the use of only 2 time points limits interpretation of the findings. We performed an extensive 
time-course (5 time points, spanning ~4 weeks) of transcriptomic profiling in skeletal muscle of pigs during 
administration of BA and GH to identify molecular events associated with a muscle anabolic response. Given 
their similarities to humans, pigs are becoming an increasingly popular animal model for biomedical research28, 
thus the information generated herein is of value to both agricultural and biomedical sciences.
Results
Growth performance during 27 days administration of anabolic agents. Carcass weights dis-
played a significant treatment (p = 0.002) and treatment x time interaction (p < 0.001) during treatment with 
anabolic agents (Fig. 1A). Average carcass weight across the entire time-course was highest in pigs treated with 
BA (72.05 kg), whilst GH (70.77 kg) and the controls (70.5 kg) were similar (standard error of difference (SED): 
0.47). Treatment with anabolic agents also caused an effect on ST and VLAT muscle weights (treatment effect: 
p = 0.075 and p < 0.001, respectively; Fig. 1B,C). Treatment group averages for ST and VLAT muscle weights 
across the 27-day treatment were highest in BA treated pigs; ST: 416.2 g for BA, 399.5 for GH, and 395.2 g for C 
(SED: 9.88); VLAT: 343.5 g for BA, 314.2 g for GH, and 326.3 g for C (SED: 6.84). Taken together, average carcass 
and muscle weights during the 27-day course of treatment were significantly higher in BA treated pigs compared 
to controls, whereas the growth effect of GH treatment was negligible.
We observed a consistently enlarged liver in pigs treated with GH (treatment effect: p < 0.001; treatment x 
time interaction: p = 0.053; Fig. 1D). The average liver weight was 1.81 kg for GH versus 1.53 kg for controls and 
1.49 kg for BA (SED: 0.028). Following 27 days of treatment with anabolic agents, there was no change in back fat 
depth (p = 0.808) or daily feed intake (p = 0.369; Fig. 1E,F).
Differentially expressed microarray probes with BA and GH treatment. Relative to the control 
group, treatment with BA caused more differentially expressed probes at all time points studied compared to GH 
treatment (Fig. 2A). This effect was more pronounced at the latter time points, with at least 50% fewer probes 
changing with GH compared to BA from day 7 onwards (Fig. 2A). BA and GH treated animals shared between 
93 and 514 differentially expressed probes at any given time point during the 27 day time course, with the largest 
overlap occurring at days 1 and 3 (502 and 514 probes, respectively; Fig. 2A). The number of probes changing in 
response to BA and GH treatment decreased with time following the first day of treatment before sharply increas-
ing again between 13 and 27 days of treatment (Fig. 2A).
Dynamic alterations in myosin heavy chain mRNA isoform expression by BA treatment. A 
large number of microarray probes for myosin heavy chain (MyHC) isoforms displayed differential expression by 
BA treatment (p < 0.05). Quantification of MyHC isoform transcript abundance by Q-RT-PCR confirmed these 
observations (Fig. 2B–E). Dynamic alterations amongst the type II MyHC mRNA isoforms occurred with treat-
ment (MyHC IIA (Myh2): p < 0.001, MyHC IIX (Myh1): p = 0.021 and MyHC IIB (Myh4): p < 0.001; Fig. 2C–E), 
with no change in expression of the MyHC I (Myh7) mRNA isoform (p = 0.57; Fig. 2B). Relative to the control, 
BA treatment increased MyHC IIB (Myh4) mRNA expression at all time points (Fig. 2E). Expression of MyHC 
IIA (Myh2) mRNA was reduced by BA treatment in four of the five time points studied, with treatment effects 
occurring in a time dependent manner (treatment-time interaction: p = 0.035; Fig. 2C). These data indicate a 
transition to faster MyHC mRNA isoforms with BA treatment. No alterations in MyHC mRNA isoform expres-
sion occurred during the 27 days of GH administration (Fig. 2B–E). Transcript abundance of Eno3 and Idh2 
were used as markers of glycolytic and oxidative gene expression, respectively (Fig. 2F,G). Eno3 and Idh2 mRNA 
expression were elevated and reduced, respectively, by BA treatment relative to the controls at all time points 
studied (Fig. 2F,G). These findings implicate a shift in metabolic gene expression with BA but not GH treatment.
MaSigPro clustering of differentially expressed probes: identification of amino acid metabo-
lism genes. To identify novel gene targets associated with growth promoter administration, we did not use 
conventional pathway or gene ontology analyses. Instead, we utilized a mathematical clustering approach to iden-
tify groups of differentially expressed probes/genes based on their pattern and magnitude of change in response 
to treatment and time. Probes from each treatment were independently clustered against the controls (BA versus 
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3Scientific RepoRts | 6:28693 | DOI: 10.1038/srep28693
control; GH versus control). Using a stringency R2 value of 0.5, a subset of differentially expressed probes clus-
tered into 9 groups for BA (Fig. 3) and zero groups for GH. Due to a low magnitude of change and concurrent 
variability amongst probes from the GH treated group, a lower stringency R2 value of 0.2 was required to generate 
a similar number of clusters to that observed with BA (Fig. 4). This approach yielded 12 clusters of differentially 
expressed probes for the GH treated group, albeit with less well-fitted regression curves (Fig. 4B). Accordingly, 
these clusters revealed a generally lower magnitude of change in gene expression by GH treatment in comparison 
to that induced by BA treatment. Furthermore, it is noteworthy that almost 78% of the clustered probes for the BA 
treatment group appeared in the top 50 most significantly changed probes at day 3, highlighting that BA clustered 
probes were amongst the most profoundly changing genes at this time point. In contrast, only 11 and 7% of the 
GH clustered probes appeared in the top 50 most significantly changed probes for GH at days 1 and 3 respectively. 
Therefore, clustering of differentially expressed probes from GH treated pigs revealed only weak time-dependant 
alterations in gene expression with a low magnitude of change, whereas BA treated pigs revealed extensive tem-
poral changes in gene expression that represented a cohort of genes with a large magnitude of change. This may 
represent differential potency of BA and GH to induce direct alterations in skeletal muscle gene expression.
Despite differences in the magnitude of change by clustered probes in BA and GH treated groups, a high num-
ber of differentially expressed probes, targeting 16 different genes, were clustered in both treatment groups (all 
increasing relative to the control cohort; highlighted in grey in Figs 3A and 4A). Many of these overlapping genes 
encoded proteins involved in amino acid metabolism such as: serine/glycine/proline biosynthesis (Phgdh, Psat1, 
Figure 1. Porcine growth characteristics during 1–27 days of treatment with a beta-adrenergic agonist 
(grey bars; BA) or recombinant growth hormone (black bars; GH), compared to a control cohort (white 
bars; C). Changes in carcass weight (A), Semitendinosus (ST) muscle weight (B), Vastus Lateralis (VLAT) 
muscle weight (C) and liver weight (D) were measured. Average daily feed intake (E) and back fat depth (F) 
were measured following 27 days of treatment with beta-adrenergic agonist (BA) or growth hormone (GH) 
compared to a control cohort. Data is mean ± SEM. * Indicates a significant treatment effect with p < 0.005 
(unless otherwise stated). #Indicates a significant treatment x time interaction with p < 0.01 (unless otherwise 
stated).
www.nature.com/scientificreports/
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Figure 2. Differentially expressed microarray probes (p < 0.05) and changes in muscle fibre type-specific 
gene expression in porcine Longissimus Dorsi muscle during 1–27 days of treatment with anabolic agents. 
Numbers in the overlapping section of the venn diagrams represent shared differentially expressed probes by 
treatment with a beta-adrenergic agonist (grey circles; BA) and recombinant growth hormone (black circles; 
GH) (A). Porcine Longissimus Dorsi muscle transcript abundance of myosin heavy chain isoform genes during 
1–27 days exposure to beta-adrenergic agonist (grey bars; BA) or recombinant growth hormone (black bars; 
GH) treatment compared to a control cohort (white bars; C); Myosin heavy chain I: Myh7 (B), Myosin heavy 
chain IIA: Myh2 (C), Myosin heavy chain IIX: Myh1 (D), myosin heavy chain IIB: Myh4 (E). Metabolic genes 
Enolase 3: Eno3 (F), and Isocitrate dehydrogenase 2: Idh2 (G), were measured as indicators of glycolytic and 
oxidative gene expression, respectively. Data is mean ± SEM. n = 10 for days 1, 3, 7 and 13, whilst n = 15 for 
day 27. * Indicates a significant treatment effect with p < 0.001 (unless otherwise stated). #Indicates a significant 
treatment x time interaction with p < 0.05.
www.nature.com/scientificreports/
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Shmt2, Pycr2), tRNA synthetases (Sars, Iars, Aars), or tRNA and amino acid transporters (Xpot, Slc7a1, Slc3a2). 
Probes detecting transcripts for the growth factor, Fgf21, and growth factor binding protein, Grb10, were also 
clustered by BA and GH treatment, both displaying an increase with treatment. Compared to all other differen-
tially expressed probes in BA clustered groups, Fgf21 probes displayed the most pronounced increase and were 
consequently singularly “clustered” independently of any other probes (Fig. 3B; BA clusters 6 and 9). A number of 
probe clusters generated for BA and GH treatments also contained multiple probes for the same gene. The most 
notable recurring probes were those for Psat1 transcripts, with 7 Psat1 probes within a distinct cluster displaying 
increased expression of this gene in both BA and GH groups (BA cluster 4 (Fig. 3B); GH cluster 7 (Fig. 4B)). This 
indicated that increased gene expression of Psat1 was potentially the strongest common response across BA and 
GH treated groups (which led to later validation by Q.RT.PCR).
Not only was there an overlap in the individual probes identified by cluster analysis for both BA and GH 
treatment groups, many of these probes were similarly grouped by both treatments (BA clusters 3 and 4 (Fig. 3B); 
GH clusters 4 and 7 (Fig. 4B)). However, the temporal expression profiles of these similarly grouped probes were 
distinct during treatment with BA and GH. For instance, BA induced a tightly controlled and prolonged elevation 
in expression of probes in BA clusters 3 and 4 (Fig. 3B), with expression peaking around day 3 and gradually 
returning towards control levels by day 27, whereas GH induced only a modest, highly variable and transient 
Figure 3. MaSigPro clustering of differentially expressed microarray probes (p < 0.05) generated using 
RNA from beta-adrenergic agonist (thin dashed line; BA) treated Longissimus Dorsi (LD) muscle, 
compared to non-treated controls (solid thick line). Clustering of probes was conducted using a significance 
of p < 0.05 and a stringency R2 value of 0.5. The table of clustered microarray probes (A) displays the Probe ID 
(with gene name if known), the cluster group, and a grey square if that probe was also clustered in the equivalent 
analysis for growth hormone treated samples (see Fig. 4). The 9 clustered probe plots (B) display time on the 
x-axis (spanning the treatment duration of 1–27 days) with relative expression on the y-axis. Each plot depicts 
the expression profile of the microarray probes within that cluster for beta-adrenergic agonist (BA) treated and 
non-treated control animals. n = 10 for days 1, 3, 7 and 13, whilst n = 15 for day 27. Av. indicates average.
www.nature.com/scientificreports/
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increase of these same probes (in GH clusters 4 and 7 (Fig. 4B)), peaking on day 1 of treatment and returning to 
control levels from day 7 onwards. Therefore, both BA and GH treatment co-ordinately regulated similar groups 
of genes involved in amino acid metabolism but the resulting temporal expression and magnitude of change were 
dependent on the treatment administered.
Validation of gene targets reveals potency of BA compared to GH on metabolic gene regula-
tion. Clustering of microarray data using maSigPro revealed that both BA and GH treatment coordinately 
increased expression of genes involved in amino acid metabolism. Accordingly, transcript abundance of a subset 
of these genes was examined by quantitative PCR to affirm the temporal expression profiles induced by BA and 
GH treatments (Fig. 5A–D).
Figure 4. MaSigPro clustering of differentially expressed microarray probes (p < 0.05) generated using 
RNA from growth hormone (solid thin line; GH) treated Longissimus Dorsi (LD) muscle, compared to 
non-treated controls (solid thick line). Clustering of probes was conducted using a significance of p < 0.05 
and a stringency R2 value of 0.2. The table of clustered microarray probes (A) displays the Probe ID (with gene 
name if known), the cluster group, and a grey square if that probe was also clustered in the equivalent analysis 
for beta-adrenergic agonist treated samples (see Fig. 3). The 12 clustered probe plots (B) display time on the 
x-axis (spanning the treatment duration of 1–27 days) with relative expression on the y-axis. Each plot depicts 
the expression profile of the microarray probes within that cluster for growth hormone (GH) treated and non-
treated control animals. n = 10 for days 1, 3, 7 and 13, whilst n = 15 for day 27. Av. indicates average.
www.nature.com/scientificreports/
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Figure 5. Validating expression of enzymes involved in the biosynthesis of anabolic intermediates to 
confirm genes that were identified as differentially expressed in the maSigPro clustering analysis. Porcine 
Longissimus Dorsi muscle transcript abundance of the following genes was determined by quantitative-RT-
PCR to establish the effects of a beta-adrenergic agonist (grey bars; BA) or recombinant growth hormone 
(black bars; GH) treatment for 1–27 days, compared to a control cohort (white bars; C); Phosphoglycerate 
Dehydrogenase: Phgdh (A), Phosphoserine aminotransferase: Psat1 (B), Phosphoserine Phosphatase: Psph 
(C), the mitochondrial isoform of phosphoenolpyruvate carboxykinase: Pck2 (D), the cytosolic isoform of 
phosphoenolpyruvate carboxykinase: Pck1 (E), the muscle isoform of Pyruvate Kinase variant 1: Pkm1 (L), 
and Pyruvate Kinase variant 2, Pkm2 (M). Representative western blots (F,G) and quantification (H,I) of beta-
adrenergic agonist (BA) and growth hormone (GH) treatment effects on Longissimus Dorsi (LD) muscle protein 
expression of Phosphoglycerate Dehydrogenase: PHGDH, and mitochondrial isoform of phosphoenolpyruvate 
carboxykinase: PEPCK-M, following 3 (F,H) and 7 (G,I) days of treatment. Alpha-tubulin was used as a 
loading control. Relationship between PHGDH and PEPCK-M protein expression in porcine Longissimus 
Dorsi muscle following treatment with a beta-adrenergic agonist (grey circles), growth hormone (black circles) 
or no treatment (white circles) following 3 (J) and 7 (K) days. Data is mean ± SEM. n = 10 for days 1, 3, 7 and 
13, whilst n = 15 for day 27. * Indicates a treatment effect with p < 0.001 (unless otherwise stated). #Indicates a 
treatment x time interaction with p < 0.001. a Indicates a treatment effect with p < 0.01. §Indicates a treatment 
effect with p < 0.05.
www.nature.com/scientificreports/
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The cluster analysis identified that genes encoding the initial two enzymes in the serine/one-carbon/glycine 
(SOG) biosynthesis pathway (Phgdh and Psat1) were increased by BA and GH treatment. We examined mRNA 
expression of SOG biosynthesis pathway enzymes (Phgdh, Psat1 and Psph) and revealed significant treatment 
and treatment x time effects for all three genes (p < 0.001; Fig. 5A–C). BA treatment induced a robust and sim-
ilar temporal increase in mRNA expression of Phgdh, Psat1 and Psph, with the largest increase relative to con-
trols occurring on day 3. The initiating enzyme of the SOG biosynthesis pathway, PHGDH, also displayed an 
approximately 2-fold increase in protein expression with BA treatment at days 3 and 7 (p = 0.010 and p < 0.001, 
respectively for ANOVA; Fig. 5F–I). Interestingly, baseline transcript abundance for Phgdh, Psat1 and Psph in 
porcine skeletal muscle (n = 10) was low (crossing point values: 40, 32.4 and 30.2, respectively), indicating that 
BA-mediated induction of SOG biosynthesis pathway genes (particularly Phgdh) could have profound biosyn-
thetic consequences.
GH treatment had no effect on PHGDH protein expression at days 3 or 7 (p > 0.05 for both Dunnett’s tests; 
Fig. 5F–I), but consistent with the maSigPro clustering analysis, GH treatment did elevate Phgdh, Psat1 and Psph 
mRNA transcripts above controls at days 1 and 3 (Fig. 5A–C), just not to the same magnitude as BA.
Given the robust, coordinated up-regulation of multiple transcripts encoding SOG biosynthesis enzymes by 
BA treatment (see schematic in Fig. 6), we next assessed expression of the mitochondrial enzyme, PEPCK-M 
(encoded by the Pck2 gene), which was also identified by the maSigPro clustering analysis (Fig. 3A; BA cluster 2). 
PEPCK-M generates phosphoenolpyruvate (PEP) from oxaloacetate, which can feed into gluconeogenesis and 
subsequently biosynthetic pathways, such as the SOG biosynthesis pathway29–31 as illustrated in the schematic in 
Fig. 6. Pck2 mRNA expression displayed a strong treatment and treatment x time interaction (p < 0.001; Fig. 5D). 
Similar to the SOG pathway genes, Pck2 transcript abundance displayed marked elevation by BA, with the largest 
response occurring at day 3 and remaining elevated above control levels through to day 27. Expression of the 
Pck2 encoded protein, PEPCK-M, was increased approximately 2-fold by BA treatment at day 7 (p < 0.001 for 
ANOVA; Fig. 5G,I), but there was no effect at day 3 (p = 0.245 for ANOVA; Fig. 5F,H). GH treatment induced 
a modest and transient increase in Pck2 mRNA expression at days 1 and 3 (Fig. 5D), with no corresponding 
changes in PEPCK-M protein expression at days 3 or 7 (p = 0.245; Fig. 5F–I).
A scatter plot depicting PEPCK-M and PHGDH protein abundance at day 7 clearly shows that individual 
pigs treated with BA displayed elevated expression of both PEPCK-M and PHGDH (Fig. 5K; r = 0.81). This effect 
was less apparent at day 3 but still evident in some BA treated pigs (Fig. 5J; r = 0.64). Transcript abundance of the 
cytosolic form of PEPCK, PEPCK-C (encoded by the Pck1 gene), showed high variability and no consistent effects 
Figure 6. A schematic illustrating the relationship between glycolysis, the TCA cycle and pathways 
associated with serine/one-carbon/glycine (SOG) biosynthesis. Bold black arrows indicate enzymes that were 
up-regulated at the mRNA (Pck2, Phgdh, Psat1, Psph) and/or protein level (PEPCK-M and PHGDH) by beta-
adrenergic agonist treatment.
www.nature.com/scientificreports/
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of BA and GH treatment (treatment: p = 0.043; treatment x time interaction: p = 0.103; Fig. 5E). It is worth noting 
that the transcript abundance of Pck1 and Pck2 in porcine skeletal muscle was very low in the controls (crossing 
point values: 36.06 and 35.83, respectively), and that the BA-mediated induction of the Pck2 gene and its encoded 
protein, PEPCK-M, represents a substantial perturbation of the homeostatic control of Pck2 expression in adult 
skeletal muscle.
Pyruvate kinase splice variants 1 and 2 (PKM1/2) irreversibly convert PEP to pyruvate with differing degrees 
of efficiency32,33. Increased expression of the PKM2 splice variant (at the expense of the PKM1 variant) has been 
shown to increase the diversion of glucose carbons into biosynthetic pathways, such as the SOG biosynthesis 
pathway32–35. We measured Pkm1 and Pkm2 splice variant mRNA expression to reveal no change in response to 
BA and GH treatment (p = 0.365 (Pkm1) and p = 0.515 (Pkm2); Fig. 5L,M).
Finally, Fgf21 probes were clustered by both BA and GH treatment groups but showed a particularly pro-
nounced increase by BA treatment (Fig. 3B; BA clusters 6 and 9). Due to the very low level of Fgf21 mRNA 
expression in porcine skeletal muscle, it was not possible to generate a standard curve for relative quantifica-
tion. Instead, crossing point (Cp) values are presented, with a decrease in Cp value indicating an increase in 
mRNA expression, which illustrates that BA, but not GH, induced de novo expression of the Fgf21 transcript 
(Supplementary Fig. S2). This was confirmed by end-point PCR amplification and subsequent visualization of a 
larger fragment of the Fgf21 transcript at day 3 (see gel image in Supplementary Fig. S2). We attempted to meas-
ure FGF21 protein expression by western blot but were unable to produce reliable measurements due to the lack 
of a commercially available reliable antibody against porcine FGF21.
Discussion
Using extensive time-course transcriptomic profiling of porcine skeletal muscle, we aimed to identify molecular 
events induced by the anabolic agents, Ractopamine (a beta-adrenergic agonist; BA) and Reporcin (recombinant 
porcine growth hormone; GH). Since the control group was not injected, it is possible, albeit unlikely, that the 
injection per se contributed to the GH-mediated effects observed herein. However, the biggest effects reported 
herein were observed in the BA treated group, for which the feed only control cohort was entirely appropriate. 
Our analysis revealed extensive changes in expression of genes involved in amino acid metabolism during admin-
istration of these anabolic agents. Most notably, we identified that BA treated pigs exhibit a previously unreported 
increase in protein expression of the PHGDH and PEPCK-M enzymes in skeletal muscle. The physiological role 
of these enzymes in skeletal muscle warrants further exploration.
Growth performance. Despite the wide spread commercial use of BA and GH by pig production industries 
in the USA and Australia, we report only modest (but significant) improvements to carcass and muscle growth 
with these agents. We and others36 suspect that extensive genetic selection for fast growing pig breeds37, such as 
the one used herein, has limited their sensitivity to exogenous anabolic agents. Improvements in growth rate 
by anabolic agents in pigs is variable12,36 and the improvements reported herein are in line with the expected 
response12,36. We also checked for other biological/physiological hallmarks of a BA or GH response. For instance, 
we observed the well-documented transition in MyHC isoform gene expression with BA treatment, shifting 
towards a persistently elevated expression of the fast type IIB mRNA isoform38–40. Treatment with GH induced a 
sustained elevation in liver weight (through days 1–27), a typical response to exogenous GH administration18,38. 
Together, these responses confirmed efficacious delivery of the anabolic agents.
Extensive temporal differential expression of genes involved in amino acid metabolism and 
transport. The major finding from the cluster analysis of BA- and GH-induced differential gene expression 
was an extensive up-regulation of transcripts encoding enzymes involved in several aspects of amino acid metab-
olism. These pathways included serine/glycine/proline biosynthesis (Phgdh, Psat1, Shmt2, Pycr2), tRNA syn-
thetases (Sars, Iars, Aars), as well as tRNA and amino acid transporters (Xpot, Slc7a1, Slc3a2). This response was 
more pronounced for treatment with BA than GH, with expression profiles showing a more sustained response 
with a greater magnitude of change. Previous transcriptomic studies using rodents treated with BA have also 
identified significant alterations in metabolic gene expression26,27 but have not reported the coordinated altera-
tions in the amino acid metabolic pathways identified herein. This could be due to species-specific differential 
response to BA, differences in the class of BA used, the sensitivity of the transcriptomic technologies employed, 
or the time points selected for transcriptomic profiling. We observed the largest increase in expression of amino 
acid metabolism related genes by BA at day 3, a time-point not used by previous studies (ref. 26: days 1 and 10; 
ref. 27: hours 1 and 4) and therefore the most likely reason for this response not being previously reported. The 
time-dependent alteration in skeletal muscle gene expression identified by our cluster analysis demonstrates the 
temporal transcriptional plasticity of skeletal muscle to an exogenous stimulus.
We decided to focus on genes involved in serine/one-carbon/glycine (SOG) biosynthesis (Phgdh, Psat1 and 
Psph) because of the recent explosion of interest in this pathway to facilitate growth in rapidly proliferating cells41–45, 
with no previous reports of a role in adult skeletal muscle.
Co-ordinated regulation of SOG biosynthesis pathway genes by BA and GH administration. 
We identified a previously unreported increase in gene expression of three consecutive enzymes in the SOG 
biosynthesis pathway (Phgdh, Psat1 and Psph) in skeletal muscle of BA treated pigs. Elevated expression 
of these genes is typically restricted to highly proliferative cancer cells41–43 and proliferating embryonic stem 
cells44, with expression of these genes coordinately diminishing as cells differentiate44. Unpublished observa-
tions from our laboratory also show reduced expression of SOG pathway genes during muscle cell differentiation 
in vitro. Therefore, the BA- (and to a lesser extent, GH-) mediated increases in gene expression of SOG pathway 
genes in a terminally differentiated adult skeletal muscle (presented herein) were somewhat surprising results. BA 
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treatment induced a 2-fold increase in protein expression of PHGDH, lasting at least 5 days. PHGDH catalyzes 
the first reaction in the SOG biosynthesis pathway, converting 3-phosphoglycerate (3-PG) to phosphohydroxy-
pyruvate, effectively shunting glucose carbons away from glycolysis and into macromolecule biosynthesis32. A 
role for PHGDH has not previously been defined in skeletal muscle, but the SOG biosynthesis pathway produces 
a number of anabolic intermediates, such as serine, glycine, cysteine and phospholipids41,43,44,46, which are essen-
tial for protein synthesis and/or cell growth. Functional genomics has revealed that PHGDH is a fundamental 
regulator of SOG pathway flux and cell proliferation41,43,45,46. Overexpression of PHGDH in non-tumorigenic cells 
increases SOG pathway flux46, whilst knockdown of PHGDH in breast and lung cancer cells reduces flux through 
this pathway41,43.
Hyperactivity of the SOG pathway, induced by elevated expression of PHGDH or PSPH, confers a significant 
growth advantage in many proliferating cell types41,43,45,46. The identification of a coordinated increase of SOG 
pathway genes by BA treatment, and to a lesser extent GH treatment (presented herein), is novel and suggests this 
pathway may also yield anabolic intermediates to support the growth of terminally differentiated muscle, which 
warrants further exploration. Sustained treatment with a BA is well documented to impair oxidative metabolism 
in skeletal muscle and induce a more fast-contracting, glycolytic phenotype38,40,47,48. Yet it has remained unknown 
as to how or why this metabolic shift, from oxidative to glycolytic, may be instrumental in BA-induced muscle 
hypertrophy. A switch to a glycolytic metabolism in cancer cells occurs not to rapidly supply ATP but to support 
increased biosynthesis of molecules required for cell growth32. The BA-mediated switch to a more glycolytic phe-
notype may also occur to support a requirement for increased diverted flux of glucose carbons through biosyn-
thetic pathways, as indicated by the coordinated increase in expression of SOG pathway genes presented herein. 
Functional studies are needed to test this hypothesis.
Serine is a nutritionally non-essential amino acid, but is considered metabolically indispensable31, serving 
as an intermediate for many cellular processes. Treatment with a BA may increase reliance on SOG pathway 
derived products such as serine and glycine, potentially for protein synthesis20,23, thus increasing expression of 
SOG pathway enzymes to meet this demand. The coordinated increase in SOG pathway gene expression in BA 
and GH treated animals may also indicate that serine (and glycine) become limiting following administration of 
anabolic growth promoters. 
The amino acids, serine and glycine, are not the only end products of the SOG biosynthesis pathway. 
Metabolomic analysis following knockdown of PHGDH in rapidly growing cells reveals a dramatic reduction 
in alpha-ketogluterate (aKG). The transaminase, PSAT1, regulates the second step in the SOG pathway and pro-
duces aKG from glutamate. aKG can restore TCA cycle flux31,41,44,49 or be used as a precursor for synthesizing 
other amino acids such as proline, arginine and glutamate32,49. Based on the data generated herein, functional 
studies are required to examine a) whether BA’s divert carbon flux into the SOG biosynthesis pathway and b) 
examine the physiological implications of increased PHGDH levels per se on skeletal muscle mass and function.
Increased expression of PEPCK-M (Pck2) by BA implicates gluconeogenic flux in skeletal mus-
cle growth. We report that BA treatment increased skeletal muscle expression of PHGDH, an enzyme capa-
ble of controlling carbon flux into the SOG biosynthesis pathway in rapidly growing cells41–43. We searched our list 
of BA clustered genes for metabolic enzymes that could divert carbon flux towards the SOG pathway. PEPCK-M 
(encoded by Pck2) converts mitochondrial oxaloacetate to phosphoenolpyruvate (PEP) and thereby supplies car-
bons from TCA cycle intermediates into gluconeogenic and biosynthetic pathways29–31. The robust increase in 
PEPCK-M mRNA and protein expression by BA treatment was considered biologically interesting given the very 
low or complete lack of expression of PEPCK-M transcripts or protein in adult muscle (ref. 50 and this study).
There are two PEPCK isozymes, a cytoplasmic form, PEPCK-C (encoded by Pck1), and the mitochondrial 
form, PEPCK-M (encoded by Pck2). Although the role of PEPCK-C has been thoroughly characterized in liver 
for its role in gluconeogenesis, its counterpart isozyme, PEPCK-M, has remained astonishingly under explored30. 
Recent reports, however, revealed a role for PEPCK-M in supporting tumour growth and cell proliferation, 
particularly in metabolically unfavorable environments29,51,52. Carbon labeling studies have demonstrated that 
knockdown of PEPCK-M or use of the PEPCK inhibitor, MPA, inhibits incorporation of oxaloacetate-derived 
carbons into serine and glycine29. This implicates PEPCK-M as an enzyme capable of redirecting TCA cycle 
intermediates into the SOG biosynthesis pathway29. The findings presented herein that BA treatment coordinately 
up-regulates expression of PEPCK-M and the first enzyme in the SOG biosynthesis pathway, PHGDH, is there-
fore particularly interesting. This coordinated response provides strong rationale for future studies to explore the 
role of PEPCK-M and PHGDH in diverting metabolic flux towards increasing biosynthetic outputs in terminally 
differentiated skeletal muscle.
Expression of Fgf21 mRNA in porcine skeletal muscle by BA treatment. The most profoundly 
changing probe in the maSigPro clustering analysis for BA and GH treatment was for the Fibroblast Growth 
Factor 21 gene, Fgf21. Analysis of Fgf21 transcript abundance in porcine skeletal muscle revealed very low basal 
expression and that BA treatment induced expression of Fgf21 mRNA expression following 3 days of treatment. 
We were unable to monitor whether this change at the transcript level resulted in an increase in FGF21 protein 
expression due to a lack of reliable antibodies detecting porcine FGF21. Recent studies implicate FGF21 as a 
modulator of insulin sensitivity and glucose uptake53, and also as a sensor of protein restriction54, suggesting this 
growth factor may facilitate compensatory metabolic functions. Further studies are required to examine whether 
BA treatment influences skeletal muscle FGF21 expression at the protein level, as well as the functional signifi-
cance of any transient increase in skeletal muscle expression.
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Conclusion
For the first time, we show that BA treated pigs exhibit increased expression of PHGDH and PEPCK-M in skeletal 
muscle. These enzymes are known to regulate flux of glucose carbons into biosynthetic pathways for the genera-
tion of anabolic intermediates. We are now conducting studies to establish whether PHGDH and PEPCK-M are 
capable of driving or modulating a muscle anabolic response.
Materials and Methods
Experimental design. Pigs administered with a beta-adrenergic agonist (BA) or recombinant growth hor-
mone (GH) were compared to a control cohort over a 27-day time course (1, 3, 7, 13 and 27 days) to elucidate 
molecular events associated with acute and sustained exposure to muscle anabolic agents.
There is no sham-injected control for the GH treatment included in this study. This study examined the effects 
of 2 treatments (BA and GH), which includes both the agents used and the associated administration practices 
used commercially. Therefore the commercial use of Reporcin (Growth Hormone) includes the injection and this 
is considered part of the treatment.
Time course of growth promoter administration. Approximately 5-month-old growing gilts (Duroc x 
(Landrace x Large White); C23 × 337 progeny; purchased from PIC, UK), with a mean starting weight of 77 kg (± 7 kg), 
were obtained in 3 batches (n = 51, 51 and 63, respectively), individually housed and allowed to acclimatise in 
the Bio-Support Unit at The University of Nottingham for 7 days. Pigs were fed twice daily for 45 minutes on 
a non-pelleted, 16.7% protein finisher feed (14 MJ/kg; Target Feeds, UK) throughout the entirety of the study. 
Calculations for predicted ad libitum feed intake were based on the Akey established feed intakes for acceptable 
swine performance for standard genotypes (Brookville, OH, USA; a commercial pig feed supplier) along with 
estimations of feed intake derived from Chaosap and colleagues55. Using these figures, pigs were provided with 
30% more feed than that predicted based on their body weight, to mimic ad libitum-like feeding. Feed quantities 
were adjusted based on body weight measurements taken at the start of each week and the feed quantity remained 
unchanged for the duration of that week. Refused feed was measured to determine actual feed intake.
Following acclimatisation, pigs were provided with feed containing Ractopamine HCL (20 ppm; Elanco 
Animal Health, Grenfield, IN) or administered an intramuscular injection (approximately 70 mm behind the 
base of the ear) of recombinant growth hormone (10 mg/pig/48 hours; Reporcin, Zamira), for 1, 3, 7, 13 (n = 10 
per treatment group per time point) or 27 days (n = 15 per treatment group). Comparisons were made against 
a control cohort that received feed only (no injections). Treatment doses were selected based on doses currently 
used in commercial pig production in the USA (Ractopamine) and Australia (Reporcin). Allocation of treatment 
and time cohorts was conducted as follows: after initial weighing, pigs were allocated in groups of 3 to adjacent 
pens, based on similar initial body weights and then treatments were assigned randomly within those groups of 
3, with each group of 3 randomly assigned to a time point. This was done to ensure equivalent starting weights 
per treatment and time point, with pigs subsequently slaughtered in the groups of 3 (one for each treatment) at 
the appropriate time point. Body weights of treatment and time allocated cohorts were not different at the start 
of the intervention (Supplementary Fig. S1). The time and/or treatment allocations were blinded from all staff 
undertaking animal husbandry, during the slaughter and tissue collection, and during the molecular analyses (of 
RNA and protein). The total number of pigs completing the trial was 164 (1 GH-treated pig was removed from the 
trial due to illness unrelated to the treatment). This project was approved by the University of Nottingham Ethical 
Review Committee and was carried out in accordance with the UK Animals (Scientific Procedures) Act of 1986 
(Project Licence PPL 40/3010).
Tissue collection and analysis at slaughter. Pigs were electrically stunned prior to exsanguination and 
confirmed dead by a licenced slaughter man. A sample of the Longissimus Dorsi (LD) muscle was then isolated 
(from the 10th rib in each pig), immediately snap-frozen in liquid nitrogen and later stored at − 80 °C for RNA and 
protein analysis. The LD muscle was used for RNA analysis because it is reproducibly accessible within seconds 
after death, providing the most highly representative RNA sample of live skeletal muscle. Following removal of 
the visceral organs, the carcass weight was determined. The Semitendinosus (ST) and Vastus Lateralis (VLAT) 
muscle was then dissected and weighed as an indicator of change in muscle growth. The ST and VLAT muscles 
have a discrete origin and insertion (unlike the LD), making them suitable candidate muscles for whole muscle 
dissection and measurement. Following halving of the carcass, back fat depth was measured (at the 5th lowest rib) 
using a line ruler.
Microarray transcriptomic profiling. Total RNA was extracted from a 100 mg sample of LD muscle using 
TRIZOL reagent (Invitrogen, Paisley, UK) according to manufacturer instructions, followed by DNase treatment 
(Promega, Southampton, UK). Total RNA from all 164 pigs (5 time points, 3 treatment groups) was processed 
using Agilent Technologies one-color Low Input Quick Amp Labelling Kit according to the manufacturer proto-
col. Cyanine 3-CTP labelled cRNA was quantified using the NanoDrop 8000 (Thermo Scientific) and 1.65 μ g of 
cRNA was then hybridized onto Agilent Technologies porcine gene expression (V2) 4 × 44 k microarrays at 65 °C 
for 17 hours in a SciGene Model 777 Microarray Oven. Arrays were processed in a SciGene NoZone Workspace, 
to limit exposure to ozone, and washed and dried using the Little DipperTM Microarray Processor, Model 650C. 
Arrays were scanned with the Agilent Technologies DNA Microarray C Scanner at a resolution of 5 μ m.
Modified maSigPro clustering of microarray data. Given the extensive time-course microarray data 
set (totalling 164 samples), we applied a clustering algorithm to the differentially expressed microarray probes 
to sort probes into distinct clusters. Biologically relevant expression profiles of these probes were determined 
using an R2 coefficient, which places a value on how well a curve fits the data. BA and GH treated groups were 
independently assessed against the controls. The approach employed herein was built upon a clustering algorithm 
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described by Conesa and colleagues56 called maSigPro. To avoid giving excessive weighting to the latter time 
points (days 13 and 27), we used a transformed time scale, with the jth time point (j = 1, 2, 3, 4, 5) given by 
Tj = log(tj). Furthermore, we used a k-means clustering algorithm, which generates k clusters but we expanded 
on MaSigPro to determine an optimal value of k. A detailed description of our modifications to the maSigPro 
method is in preparation for publication in a mathematics journal and will be made available at arxiv.org.
Quantitative and end-point PCR. Expression profiles of a subset of probes identified by maSigPro clus-
tering of microarray data were validated by measuring the relative abundance of the respective mRNA tran-
scripts using quantitative reverse transcriptase PCR (Q-RT-PCR). First strand cDNA synthesis was conducted 
on 500 ng RNA using a cDNA synthesis kit (Transcriptor First Strand cDNA Synthesis Kit, Roche, Burgess Hill, 
UK) according to manufacturer instructions. Q-RT-PCR was performed in duplicate on 384 well plates using a 
Lightcycler 480 (Roche, Burgess Hill, UK). All samples were blind labelled until final analysis of the expression 
data. Details of the Q-RT-PCR were described previously57. Relative transcript abundance was calculated using 
the standard curve method and expression values were normalized to total cDNA in the PCR reaction using the 
established oligreen method58, as previously described57. End-point PCR of the Fgf21 transcript and subsequent 
visualization on a 1% agarose gel was conducted to confirm induction of Fgf21 mRNA expression. All oligonu-
cleotide sequences are presented in Table 1. Primer sequences for myosin heavy chain isoforms were obtained 
from Wimmers et al.59.
Western blotting. Total protein was extracted from frozen day 3 and 7 treated (BA and GH) and control 
LD muscle samples. The extraction, immunoblotting and detection procedures were performed as previously 
described60, using ECL select (GE Life Sciences). Antibodies for PEPCK-M, PHGDH and Alpha-tubulin were 
purchased from Cell Signaling (#6924), Sigma Aldrich (HPA021241) and Cell Signaling (#2144), respectively.
Statistical analyses. All statistical analyses were performed using Genstat (13th–15th edition) and signifi-
cance was accepted if p < 0.05. Animal growth performance data were analysed for treatment effects (BA, GH or 
control), time (1, 3, 7, 13 or 27 days) and treatment x time interactions by two-way analysis of variance (ANOVA), 
with blocking for batch of pigs. Similarly, relative changes in mRNA transcript abundance were assessed for sig-
nificant treatment, time and treatment x time interactions using two-way ANOVA (no blocking). Protein expres-
sion of PEPCK-M and PHGDH at days 3 and 7 were analysed separately for each protein and day by one-way 
ANOVA. When appropriate (i.e. no treatment x time interactions), post-hoc Dunnett’s tests were used to compare 
BA and GH group means to the control group. All data are presented as mean ± standard error of the mean.
Statistical analyses built into the maSigPro clustering package employed an ANOVA to filter differentially 
expressed probes based on p < 0.05.
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